Wednesday, June 10, 2026

Patent intelligence · US

US 2022169620

SPIRO-CYCLIC AMINE DERIVATIVES AS S1P MODULATORS

granted A61P/2500
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 16
Applicant portfolio 23
Patent details — US 2022169620

Quick answer

US 2022169620 (SPIRO-CYCLIC AMINE DERIVATIVES AS S1P MODULATORS) is held by ABBVIE DEUTSCHLAND [DE]. Status: granted. Granted Jun 2, 2022. Expires May 28, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
CPC classes
A61P/2500

More from ABBVIE DEUTSCHLAND [DE]

Related pharmaceutical patents in our USPTO index.

  1. WO 2024243450

    MÉTHODES DE TRAITEMENT UTILISANT DES CONJUGUÉS ANTICORPS-MÉDICAMENT ANTI-C-MET

    ABBVIE INC [US] · Expires Nov 23, 2044

    granted
  2. CA 3266054

    COMPOSÉS DE N-MÉTHYL-4-(QUINOLIN-2-YL)PYRIDIN-2-AMINE

    ABBVIE DEUTSCHLAND [DE] · Expires Mar 2, 2044

    granted
  3. CA 3259391

    POLYTHÉRAPIE ANTI-GARP-TGF-β1/PD-1

    ABBVIE BIOTHERAPEUTICS INC [US] · Expires Jan 27, 2044

    granted
  4. CA 3245150

    COMBINAISONS AVEC UN ANTICORPS ANTI-CD39 HUMAIN, UN ANTICORPS ANTI-PD-1 HUMAIN ET UNE CHIMIOTHÉRAPIE CONTRE LE CANCER GASTRIQUE

    TRISHULA THERAPEUTICS INC [US] · Expires Sep 2, 2043

    granted
  5. US 2023174645

    ANTI-HEMOJUVELIN (HJV) ANTIBODIES FOR TREATING MYELOFIBROSIS

    DISC MEDICINE INC [US] · Expires Jun 3, 2043

    granted
  6. CA 3235096

    METHODES DE TRAITEMENT DE L'ANEMIE CAUSEE PAR UNE MALADIE RENALE

    DISC MEDICINE INC [US] · Expires May 20, 2043

    granted
  7. CA 3207179

    METHODES DE TRAITEMENT DE LA MALADIE DE CROHN ET DE LA COLITE ULCEREUSE

    ABBVIE INC [US] · Expires Jul 9, 2042

    granted

Frequently asked questions

What is US patent 2022169620?

US 2022169620 (SPIRO-CYCLIC AMINE DERIVATIVES AS S1P MODULATORS) is held by ABBVIE DEUTSCHLAND [DE]. Status: granted. Granted Jun 2, 2022. Expires May 28, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 2022169620?

ABBVIE DEUTSCHLAND [DE] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 23 pharmaceutical patents for this assignee.

When does US 2022169620 expire?

Our index shows an expiration date of May 28, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.